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country’s rapid economic development, with a comprehensive
National Health Insurance (NHI) system in place by 1989. The funding
of medical devices has followed this progression, with incorporation
into the NHI reimbursement system in 2000 (several years later than
pharmaceuticals), but important issues affecting patient access
remain. Although the effect of devices on the NHI budget is relatively
modest (only about 4%), because of concerns about NHI sustainability,
attention has increasingly been paid to their management and
funding. Unlike pharmaceuticals, however, it has been quite challeng-
ing to develop clear and fair criteria for reimbursement coverage and
pricing of medical devices. The two key and longstanding issues
around the reimbursement of medical devices in Korea are how to
expedite market entry of improved or innovative medical devices atee front matter Copyright & 2014, International S
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.lee@medtronic.com.
ndence to: Sang-Soo Lee, Medtronic Korea Co. Ltd.,appropriate prices, and how to satisfactorily lower the reimbursement
levels of older devices, thereby making headroom for new technologies
to be reimbursed. Despite protracted discussions over the last decade,
industry and government have been unable to reach full agreement.
There has been some progress (e.g., introduction of the Value Appraisal
and the Revaluation Systems), but there remains urgent need for
productive discussion and consensus between government and indus-
try regarding reasonable funding rules, transparency, and clarity in the
reimbursement pricing process for medical devices.
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The development of health funding policy in Korea has followed
the same trajectory as the country’s economic development, with
the inaugural Medical Insurance Act enacted in 1966 and imple-
mented in 1977, a universal Medical Insurance System introduced
a mere 12 years later, and transformed since 1989 into a
comprehensive National Health Insurance (NHI) system. The
reimbursement of medical devices has expanded along with this
progression in Korean health, but important issues affecting
patient access remain. In this policy perspective article, the
current reimbursement coverage and pricing rules, and the
decision-making process are brieﬂy discussed and the major
access issues that remain are outlined.Reimbursement Decision Making
As a statutory requirement to enter the Korean market, medical
devices must ﬁrst be licensed by the Ministry of Food and Drug
Safety, which, like its international regulatory counterparts in the
United States and elsewhere, undertakes classiﬁcation and risk-
based assessment of the quality, safety, and efﬁcacy of products
[1]. The Ministry of Food and Drug Safety (previously the KoreaFood and Drug Administration) follows similar US Food and Drug
Administration classiﬁcation, with devices categorized from class
I (general controls) to class IV (requiring premarket approval).
Applications for reimbursement of a medical device must be
made to the Ministry of Health and Welfare (MOHW) within 30
days of regulatory approval by the Ministry of Food and Drug
Safety. The Health Insurance Review and Assessment Services
(HIRA) and its Medical Device Expert Evaluation Committee
(MDEEC) review the application and make a recommendation to
the MOHW, which decides reimbursement coverage and price
(Fig. 1 and Table 1). Ofﬁcially, the lead time for reimbursement
approval is 150 days; however, it usually takes signiﬁcantly longer,
particularly for devices that require health technology assessment
(HTA) evaluation before application review (because the device and
the associated procedure undergo separate reviews, see below) and
for new devices that require the establishment of coverage guide-
lines (specifying the clinical indication, etc.).
Under the Korea-US Free Trade Agreement (which took effect
March 15, 2012), suppliers may appeal MDEEC decisions through
an independent third-party review process introduced to
enhance transparency and objectivity [2]. The process, however,
is unappealing to suppliers because the lead time is also nomi-
nally 187 days and the ﬁndings are not legally binding on
the MOHW.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
5F, Sajo Building 1001, Daechi-dong, Kangnam-Ku, Seoul 135-280,
* The Health Technology Assessment (HTA) process is limited to medical devices associated with new procedures or
techniques, and for which comparable products are unavailable.
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Fig. 1 – Flow chart for the medical device reimbursement approval process.
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Although the number of devices listed for reimbursement has
steadily risen, the rate of reimbursement has not been in step
with the number of applications being made (currently more than
100/month). For instance, over the period 2010 to 2012, reim-
bursement applications grew at about 17%/year but listings
increased by only about 9% annually—and overall medical
devices continue to make up only about 4% of total NHI expendi-
ture (the size of the private, out-of-pocket, sector is unknown,
with no ofﬁcial statistics because government is not concerned
with price or utilization controls).
A particular difﬁculty is that HIRA has adopted a policy of
requiring robust evidence of efﬁcacy, safety, and cost-
effectiveness as a prerequisite for a positive reimbursement
recommendation (Table 2). This poses a major problem for the
medical device sector, in which historically (unlike pharmaceut-
icals) there has not been demand for rigorous economic and
other evidence, and therefore the Value Appraisal Standard 2
(VAS 2) criteria were introduced for applications requesting
premium prices (see below).
The MOHW announced revised regulations on February 25,
2013 (effective April 1, 2013) [3]: ﬁrst, to expedite market entry,
the reimbursement application process was shortened by differ-
entiating submissions on the basis of product characteristics and
the likely level of review complexity—a positive development
welcomed by industry. Second, the MDEEC was reorganized
1) with its pool of experts increased to 300 members (nominated
by medical societies and relevant stakeholders) to enhanceTable 1 – Medical device reimbursement approval proces
Step Process
1 Reimbursement application must be submitted
within 30 d after Ministry of Food and Drug Safety
(MFDS) approval
A
M
2 HIRA review R
C
R
C
3 Medical Device Expert Evaluation Committee
(MDEEC) review
R
C
4 Health Insurance Policy Deliberation Committee
(MOHW)
C
5 Publication of reimbursement approval notice Aexpertise, objectivity, and fair and efﬁcient operation; and 2) with
experts to attend monthly meetings to be randomly selected
from the pool and increased in number to 20. This latter reform
was opposed by all nongovernment stakeholders on the grounds
that the random selection of experts for each reimbursement
meeting was likely to result in inconsistent and poor decision
making (previously MDEEC meetings were attended by 18
experts, each of whom served a 2-year term). Nevertheless, the
new arrangements were implemented.Reimbursement Pricing Mechanism
Reimbursement decisions about new devices are usually made
on the basis of comparisons with devices already on the MOHW
list, “unreimbursed” devices (these are also listed, making up
about 10% of the total), and the relevant procedure fee. New
devices are then placed into one of three categories: reimbursed,
funded under the procedure fee, and unreimbursed.
“Reimbursed” category: A device is reimbursed by brand, with
its own code and price, and can be claimed for separately. The
reimbursement level is determined by comparing the product
with those already listed and in the same “functional category.”
In this context, the functional category of a medical device is
determined by considering both its indication for use and three
physical characteristics: compositional material, shape, and size;
for instance, all pacemakers, regardless of manufacturer and
brand, are placed in the same functional category. Most new
medical devices are determined at the lowest price, or 90% of thes.
Process description
pplication to the Ministry of Health and Welfare (MOHW) or Health
Insurance Review and Assessment Services (HIRA).
anufacturers, medical institutions, and medical societies may
submit applications.
eview of appropriateness of coverage and reimbursement price.
onsideration of eligibility for reimbursement and estimation of
budget impact.
eview of comparable devices already listed.
omparison of cost-effectiveness with currently listed devices
(by reviewing the application, the literature, seeking medical
society opinion, etc.). Collation of internal/external expert opinion.
ecommendation on reimbursement coverage and price made within
100 d of application.
onsideration of economic feasibility (i.e., substitutability and
cost-effectiveness) and appropriateness for funding.
onﬁrmation of decision about reimbursement coverage and
price.
pproval notice published on the MOHW Web site within 150 d of
application.
Table 2 – Evidence requirements by HIRA for medical device reimbursement applications, decision appeals,
and revaluation.
Application category Evidentiary requirement
Reimbursement application New application Copy of MFDS approval letter
Details of product price calculation included in the reimbursement application
Evidence supporting cost-effectiveness
Documents detailing foreign and domestic utilization of the device
Details of device composition and componentry
Supporting reports from the literature
Other supporting documents
Decision appeal Documents detailing the grounds for appeal
Details of the appeal
Details of the calculation of the reimbursement price being appealed
Other supporting documents
Revaluation Common appraisal MFDS approval letter
Evidence supporting cost-effectiveness, including comparative information
Details of device composition and componentry; product manual
Product sample
Import price/manufacturing cost, domestic and foreign market prices
Value appraisal* Evidence for clinical efﬁcacy and effectiveness, including patient beneﬁts
Economic evidence including cost-effectiveness analysis
Documents supporting R&D costs
Documents supporting technology creativity and product uniqueness
Foreign government/institution-issued ofﬁcial regulatory documentation
Other supportive information
HIRA, Health Insurance Review and Assessment Services; MFDS, Ministry of Food and Drug Safety.
* The additional documents required if a premium reimbursement price is sought.
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for a new device considered signiﬁcantly superior, reimburse-
ment is determined by application of VAS 2 criteria (see below)
and a new functional category is created (Table 3).
“Funding under procedure fee” category: Devices in this
category (e.g., syringes, disposable needles, and similar products)
are generally considered consumables and included in the pro-
cedure fee (which also includes both hospital and physician fees).
Unreimbursed category: Devices in this category are those
that the MOHW assesses as not deserving reimbursement, and
therefore they must be funded by patients out of pocket. At the
end of 2012 there were 1770 products in this category; most are
expensive or devices considered not clinically essential, but there
is no clear guidance about which characteristics determine their
out-of-pocket classiﬁcation and ineligibility for reimbursement.
If a new device is innovative and dissimilar from listed
products in the same functional group, its reimbursement price
is determined by considering various factors, for example, man-
ufacturing costs (or importation costs), clinical safety and efﬁ-
cacy, economic impact, and so on. In most cases, an innovativeTable 3 – “Reimbursed” medical device category: Reimbu
In comparison with listed devices in the same functional category, the co
effectiveness, or clinical performance of the new device is
equal or similar
superior
signiﬁcantly superior
inferior
Relevant functional group(s) assessed through the Revaluation System.device is associated with an innovative procedure or interven-
tional technique, and therefore both must undergo the HTA
evaluation process before an application for reimbursement can
be considered.
Issues
Many single-use devices are in the funding under procedure fee
category, and because their real costs are not properly reﬂected in
the procedure fee, problems associated with inappropriate reuse
arise. Despite MFDS approval, innovative devices that differ from
anything available cannot enter the Korean market without an
HTA review. Unfortunately, for lack of evidence of “cost-effec-
tiveness” (there being no clear deﬁnition, for example, an incre-
mental cost-effectiveness ratio threshold or range), most of these
are then classiﬁed as unreimbursed. Both industry and the MFDS
have expressed their concerns that these negative outcomes
raise issues of equity of access and argue that the current HTA
review system is a signiﬁcant barrier to access by patients to
innovative devices.rsement-level criteria and awards.
st, In comparison with listed devices in the same functional
category, the reimbursement price level awarded is
90% of the listed price or equal to the lowest price
equal to the highest ceiling price
equal to the highest ceiling price þ Value Appraisal Standard
2 premium
o90% of the listed price or equal to the lowest price
Equal to the functional price (e.g., all brands of drug-eluting
stents would get the same price)
Table 4 – Value Appraisal Standards 1 and 2: Assessment criteria for reimbursement level for new devices.
Value appraisal* Appraisal category Factor
Standard 1† Procedure Minimizes invasiveness.
Facilitates the procedure.
Reduces procedure time.
Improves accuracy of procedure.
Function Improves functions, e.g., ﬁxation strength.
Improves biocompatibility.
Cost Reduces costs of other medical devices or drugs.
Increases device longevity because of enhanced durability.
Patient Reduces pain, discomfort, etc.
Improves safety.
Other Other factors.
Standard 2 Therapeutic effects (clinical usefulness) Improved therapeutic effects.
Reduce complications, adverse effects, or infection rates.
Reduced disease recurrence or reintervention rates.
Cost-effectiveness Increased longevity due to enhanced durability.
Reduced use and costs of other devices or medicines.
Reduced hospital stay and treatment period.
Reduced operating time.
Quality-of-life beneﬁts Reduced pain/discomfort.
Increased clinical beneﬁt.
Improved independence.
* “Level of improvement” in each appraisal category is scored on a 5-point scale: none, slight, moderate, signiﬁcant, and considerable.
† The highest ceiling price is granted when the new device receives level 3 (“moderate”) improvement in two or more appraisal categories.
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Value Appraisal Standard 1 (VAS 1) was created to address the
problem of new devices being reimbursed at lower levels than
older products. The MOHW recognized that incremental improve-
ments, short life cycles, and a lack of robust clinical evidence are
characteristics of the device sector, and therefore provided
criteria, based on evidence of improvements in compositional
material, shape, and size, for funding new technologies at the
highest ceiling prices for listed products (Table 4). For instance,
because the improved functional characteristics of new ortho-
paedic implants composed of more durable materials and
designed to enhance patient comfort cannot easily be substanti-
ated at the time of reimbursement application, the mechanical or
bench-test data submitted for regulatory approval can be used to
support a claim under VAS 1.
In addition, if there is supportive evidence that a new device is
signiﬁcantly superior to comparable listed products (in terms of
cost, effectiveness, and performance, for example), it may be
granted a premium (up to 50%) through VAS 2 (Tables 4–6). The
MDEEC, or an advisory subcommittee representing the relevant
medical societies and other stakeholders, decides the
premium price.Table 5 – Value Appraisal Standard 2: Scoring system for
devices.
Appraisal category (maximum score)
1 (none) 2 (sligh
Therapeutic effects; clinical usefulness (25) 0 6.25
Cost-effectiveness (15) 0 3.75
Quality-of-life beneﬁts (10) 0 2.5
* Level of improvement (LOI) score totals are grouped into 5 ordinal cat
premiums over comparable listed products (from 10% to 50%) are allocIssues
Although the MOHW meant well by establishing the VAS 1 and
VAS 2 criteria, and they provide useful solutions in principle, in
practice they are not used often (perhaps to minimize expenditure,
for instance, by avoiding the creation of new functional categories
under VAS 2); for example, in 2010, only 5.6% of the devices (93 out
of 1653 applications) were granted the highest ceiling prices, and
only 4 devices (0.2% of applications) obtained premium prices,
which at best were only 20% higher than those of listed compara-
tors [4]. VAS 1 and VAS 2 are useful tools to guide appropriate
pricing decisions, if they are properly used. Unfortunately, HIRA
does not actively use them, and pricing decisions using VAS 2 are
sometimes unreasonable. For instance, recently, a new deep brain
stimulator (for Parkinson’s disease) with improved device longev-
ity, which eliminates the need for a second implantation proce-
dure, was granted only a 20% premium price; as a result, the device
remains off the market and the manufacturer continues to appeal
for a more appropriate reimbursement.The Revaluation System
The Revaluation System was introduced in 2010 with the follow-
ing objectives (in order): to improve unfair pricing rules, to secureassessment of premium reimbursement level for new
Level of improvement*
t) 3 (moderate) 4 (signiﬁcant) 5 (considerable)
12.5 18.75 25
7.5 11.25 15
5 7.5 10
egories (“Z10–˂20” to “50”), according to which the percentage price
ated; for example, an LOI of 35 would attract a premium of 30%.
Table 6 – Value Appraisal Standard 2: Scoring sys-
tem for allocation of premium reimbursement level
for new devices.
Total level of
improvement score
Percentage price premium over
comparable listed products
Z10–o20 10
Z20–o30 20
Z30–o40 30
Z40–o50 40
50 50
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category” groups, and to enhance the efﬁciency of the device
management system. To resolve the “90% or lowest price rule”
issue, the MOHW introduced two new rules: to grant a single
price to products in the same functional category and to grant
premium prices through the application of VAS 1 and VAS 2 (as
outlined above).
The Revaluation System requires manufacturers to submit the
documents and dossiers listed in Table 2. Medical devices with
signiﬁcant clinical and economic superiority can acquire a pre-
mium (up to a maximum 50%) over the “single functional
category” price. Adjustments for medical devices revaluated in
2010 were to take effect in 2011, with revised functional category
classiﬁcation and prices. Because there were more than 14,000
devices listed in 2010, completing the revaluation in time was
impossible; therefore, the MOHW aimed to complete the ﬁrst
round of the Revaluation System by the end of 2012.
Issues
Because the single functional category price (that is to say, one
price for all devices in the same functional category) is calculated
using a weighted average based on the most recent year’s claim
volumes and prices, under the Revaluation System in some cases
low reimbursement prices were raised and vice versa. MOHW’s
original plan to complete the ﬁrst Revaluation round by the end
of 2012 was not achieved; it is now expected to be completed
around mid-2014.Reimbursement Price Adjustment: Actual
Transaction Price Mechanism
The Actual Transaction Price system was introduced to adjust
reimbursement prices using a market mechanism, as follows:
HIRA investigates market prices at the hospital level in a random
sample of transactions (or sometimes manufacturers’ selling
prices are audited), and where gaps between reimburse-
ment level and actual purchase price are found, reimbursement
is adjusted (lowered usually) to the level of the hospital
purchase price.Reimbursement Price Adjustment: Foreign Exchange
Rate Mechanism
This price adjustment mechanism was adopted to allow for
foreign exchange rate ﬂuctuations. The Korean device industry
is heavily dependent on imports (about 64.9% overall in 2011, and
a higher proportion for products in the reimbursed category) and
therefore supply is sensitive to external economic variables,
particularly foreign exchange rates. When exchange rates sud-
denly skyrocketed during the global ﬁnancial crisis (September
2008), the MOHW and industry reached agreement to develop apricing rule reﬂecting ﬂuctuations in foreign exchange rate; this
was announced on April 10, 2009 (effective April 15, 2009) [5].
Essentially, reimbursement price adjustments, reﬂecting
exchange rate changes against the US dollar (for convenience),
may be implemented every 6 months (on April 1 and October 1)
against the baseline reimbursement price on April 1, 2009.Medical Device Management: Unresolved Issues
Most of the medical devices have been incorporated into the NHI
reimbursement system only since 2000 (unlike pharmaceuticals,
which were included years earlier). Although the effect of devices
on the NHI budget is small (about 4%), attention has increasingly
been paid to their management and funding (including the
introduction of HTA review) as a result of concerns about
sustainability of the NHI system. Although the criteria for
reimbursement coverage and pricing of pharmaceuticals are clear
and local economic evaluation guidelines are available, the
development of correspondingly clear and fair criteria for medical
devices in Korea has proved very challenging, and the current “4th
hurdle” process is far behind those in established major European
markets; for instance, HTA of innovative devices is undertaken by
National Evidence-based Healthcare Collaborating Agency, the
Korean HTA agency, but afterwards pricing and reimbursement
decisions are made independently by a completely separate
ofﬁce, HIRA. Despite considerable controversy, lengthy discus-
sions, repeated examinations of foreign device management
systems, and similar initiatives, there has been very little prog-
ress toward achieving transparent and clear pricing rules for the
reimbursement of devices.
A major factor contributing to the ongoing lack of clear criteria
regarding reimbursement coverage and pricing rules lies in the
nature of the medical device industry itself. Typically, the clinical
evidence supporting product value is poor—largely because it is
not required for licensing, but also because of short product
lifecycles (usually o2 years) and the difﬁculty of conducting
longitudinal comparative effectiveness research with devices
[6]. Therefore, it is unreasonable to simply expect policies
designed for and applied to pharmaceuticals (which have a very
different path to market) to also apply to medical devices.
Nevertheless, clearly the link between value and reimbursement
level must apply to all medical technologies—which makes the
lack of evidence for devices a fundamental problem and a global
one, with the foreign countries that Korean authorities reference,
for example, Taiwan and France, facing similar difﬁculties [7,8].
There is no simple and generalizable solution. At a minimum,
however, evidence on the beneﬁts, potential harms, and esti-
mates of the costs should be presented whenever possible for all
classes of medical devices to inform decision making. To its
credit, the MOHW recognized this peculiarity of the devices sector
and introduced VAS 1 and VAS 2 and the Revaluation System
processes as solutions (Table 4)—which they would indeed be in
practice, if only they were used consistently, transparently, and
in a timely manner.
A recommendation to improve the reimbursement process in
the short term would be to apply the VAS (1 and 2) and
Revaluation System processes consistently, transparently, and
in a timely manner. To address the evidence-pricing-access
problem in the longer term, a recommendation would be that
Korean authorities consider adopting a differentiated approach to
the level of evidence required for appropriate reimbursement,
perhaps on the basis of the medical device’s beneﬁts to patients
and effect on the national health insurance budget. For example,
if a medical device is expected to bring signiﬁcant beneﬁts to
patients but also substantially affect the insurance budget, it
might be reasonable to require more robust supportive evidence.
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called coverage with evidence development) and performance-
based reimbursement would be worth exploring in the Korean
context [9]. This would, of course, require the MOHW and related
authorities to develop a regulatory environment conducive to
evidence development—and for their part, medical device man-
ufacturers to make greater efforts to generate appropriate clinical
and economic evidence to support the value of their innovative
products.
As its counterparts in every other developed country, the
MOHW is in the service of the Korean government and executes
its policies as directed. To improve reimbursement coverage and
pricing practice in the longer term, a further recommendation,
however, would be to improve the governance and transparency
of the principal decision-making bodies; for example, making the
outcomes of appeals against MDEEC decisions binding on
the MOHW.Conclusions
The two critical and longstanding issues around the reimburse-
ment of medical devices in Korea are how to expedite market
entry of improved or innovative medical devices at appropriate
prices, and how to appropriately lower the reimbursement levels
of listed older devices, thereby making headroom for improved or
innovative technologies. Unfortunately, despite protracted dis-
cussions over many years, industry and government have been
unable to reach consensus, with government holding the position
that it cannot concede higher reimbursement prices for improved
or innovative devices without an established mechanism to
reduce reimbursement for older technology, while industry
maintains the opposite position, that it cannot accept a price-
lowering mechanism for older technology while unfavorable
pricing rules for improved or innovative technologies remain.
In conclusion, over the last decade there has been little
signiﬁcant improvement in the reimbursement coverage and
pricing rules for medical devices in Korea. Although there hasbeen some incremental progress in the regulations (e.g., the
introduction of the Value Appraisal System and Revaluation
System), there remains large scope for improvement. More
productive discussion between funding authorities and industry
regarding reasonable rules and transparency in the pricing
process are urgently required—Korean patients deserve no less.
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